Monitoring fibrillar collagen turnover in hypertensive heart disease

Cardiovascular Research

Volumn 35, Issue 2, 1997, Pages 202-205

  Díez, Javier ^a   Laviades, Concepción ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL SAN JORGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROCOLLAGEN TYPE 1 CARBOXYPROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CONTROLLED STUDY; HEART DISEASE; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SERODIAGNOSIS; STRAIN DIFFERENCE;

ANIMALS; BIOLOGICAL MARKERS; COLLAGEN; HUMANS; HYPERTENSION; MYOCARDIUM; PEPTIDE FRAGMENTS; PROCOLLAGEN; RATS; RATS, INBRED SHR;

EID: 0343554659     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00072-2     Document Type: Review

References (31)

1. Jalil JE, Doering CW, Janicki JS, Pick R, Clark WA, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989;64:1041-1050.
2. Pardo-Mindán FJ, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J 1993;14(suppl J):12-14.
3. Weber KT, Eghbali M. Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc Rev Rep 1991;12:61-69.
4. Weber KT, Sun Y, Guarda E, et al. Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Eur Heart J 1995;16(suppl C):24-28.
5. Hess OM, Schneider J, Kock R, Bamert C, Grimm J, Krayenbuehl HP. Diastolic function and myocardial structure in patients with myocardial hypertrophy. Circulation 1981;63:360-371.
6. McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990;3:735-740.
7. Strauer BE. The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol 1990;15:775-783.
8. Nimni ME. Fibrillar collagens: their biosynthesis, molecular structure, and mode of assembly. In: Zern MA, Reid LM, editors. Extracellular Matrix. New York: Marcel Dekker, 1993:121-148.
9. Smedrod B, Melkko J, Risteli L, Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via a mannose receptor in the liver endothelial cells. Biochem J 1990;271:345-350.
10. Risteli L, Risteli J. Noninvasive methods for detection of organ fibrosis. In: Rojkind M, editor. Focus on connective tissue in health and disease. Boca Raton, FL: CRC Press, 1990:61-98.
11. Schuppan D. Connective tissue polypeptides in serum as parameters to monitor antifibrotic treatment in hepatic fibrogenesis. J Hepatol 1991;13(suppl 3):S17-S25.
12. Savolainen ER, Goldberg B, Leo MA, Velez M, Lieber CS. Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease. Alcoholism Clin Exp Res 1984;8:384-389.
13. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-436.
14. Raedsch R, Stiehl A, Sieg A, Walther S, Kommerell B. Biliary excretion of procollagen type III peptide in healthy humans and in patients with alcoholic cirrhosis of the liver. Gastroenterology 1983;85:1265-1270.
15. Trinchet JC, Hartmann DJ, Paterson D, et al. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis: relationship to liver histology and conventional liver tests. J Hepatol 1991;12:139-144.
16. Low RB, Cutroneo KR, Davis GS, Giancola MS. Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest 1983;48:755-759.
17. Horslev-Petersen K, Bentsen K, Junker P, Lorenzen I. Serum aminoterminal type III procollagen peptide in rheumatoid arthritis. Arthritis Rheum 1986;29:592-599.
18. Janicki JS. Collagen degradation in the heart. In: Eghbali-Webb M, editor. Molecular biology of collagen matrix in the heart. Austin, TX: RG Landes, 1995:61-76.
19. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-640.
20. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993;8:127-132.
21. Autio P, Risteli J, Kiistala U, Risteli L, Karvonen J, Okarinen A. Serum markers of type I collagen synthesis and degradation in skin diseases: altered levels in diseases with systemic manifestations and during systemic glucocorticoid treatment. Arch Dermatol Res 1993;285:322-327.
22. Díez J, Panizo A, Gil MJ, Monreal I, Hernández M, Pardo Mindán J. Serum markers of collagen type I metabolism in spontaneously hypertensive rats. Relation to myocardial fibrosis. Circulation 1996;93:1026-1032.
23. Díez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995;91:1450-1456.
24. Laviades C, Mayor G, Díez J. Treatment with lisinopril normalizes concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens 1994;7:52-58.
25. Laurent GL. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987;252:C1-C9.
26. Díez J, Hernández M. Is depressed the extracellular degradation of collagen type I fibers in spontaneously hypertensive rats with myocardial fibrosis?. Circulation 1996;94:2998.
27. Kaplan HR, Taylor DG, Olson SC, Andrews LK. Quinapril: a preclinical review of the pharmacology, pharmacokinetics and toxicology. Angiology 1989;40:335-350.
28. Beerman B, Till AE, Gomez HJ, Hichens M, Bolognese JA, Junggren I. Pharmacokinetics of lisinopril (i.v./p.o.) in healthy volunteers. Biopharm Drug Dispos 1989;10:397-409.
29. Brilla CG, Maisch B, Rupp H, Funck R, Zhou G, Weber KT. Pharmacological modulation of cardiac fibroblast function. Hertz 1995;20:127-134.
30. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-195.
31. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995;95:1353-1362.